


10X Essentials

Infectious Disease Diagnostics in the Geisinger Health System

A Publication of Geisinger Medical Laboratories
Vol. (6):1-3, December 15, 2012




Influenza/Respiratory syncytial virus (RSV) Report

- GML reports a large increase in influenza virus activity this week, mostly influenza A, Seasonal H3 (63%), with some Influenza A, H1N1 reported (4%). Some viruses are not typed.
- Influenza B virus continues to circulate to a lesser extent than influenza A (refer to bar graph)
- There was an increase in the proportion of RSV in our sample set (refer to bar graph).

ALERT: The Centers for Disease Control and Prevention reports widespread influenza activity in PA, New York, and Ohio.

FYI: My route from Arizona across the U.S. this past week was uneventful. After 2,412 miles, I arrived in Pennsylvania this Wednesday safe and sound. I look forward to begin working with you on January 7, 2013.

dmw



Weekly Summary, RESPView Pathogen Surveillance 2012-2013

In CDC weeks 50, ending December 15, 2012, influenza predominates, followed by rhinoviruses and RSV. The diversity of viruses is high with representative viruses from all viral groups. 52% of samples submitted were positive for at least one virus. The first *Bordetella pertussis* was detected this week.

Questions: For newsletter questions, contact Interim Microbiology Laboratory Director, Dr. Harold Harrison at 570-271-7443 or me via Christy Attinger at (570) 271-6338.


Best regards, Donna M. Wolk, MHA, Ph.D., D(ABMM), GML Director of Microbiology, as of January 7, 2013

GEISINGER
MEDICAL LABORATORIES

"Make it the best." - A. Geisinger

**GML RespVIEW
2012-2013**

Respiratory Viruses



	CDC week 41	42	43	44	45	46	47	48	49	week 50 ending 12/15
adenovirus	0	0	0	0	1	1	0	1	0	2
coronavirus	0	0	1	0	2	4	2	7	8	17
human metapneumovirus	0	2	1	0	0	0	1	0	2	3
influenza A	0	0	1	0	0	1	0	1	24	49
influenza B	1	0	0	0	0	1	0	1	5	10
parainfluenza	12	16	8	17	11	17	8	15	13	8
respiratory syncytial virus	1	1	3	9	13	9	21	19	24	35
rhinovirus	35	39	29	28	33	41	26	33	28	44
% Positive Rollup					37%	51%	39%	44%	45%	52%